Topic:

Big Data

Latest Headlines

Latest Headlines

U.K. and Canadian governments back bioinformatics, omics research projects

British government funding groups are looking for startups that will sustain the resurgence in the country's economy. And that means more money for bioinformatics businesses, with the Technology Strategy Board accepting applications for new funding from next month.

Merck vaccine plant taps R&D's Big Data platform to solve yield conundrum

Having invested in data analytics platforms in recent years, pharma R&D labs are working to develop the drugs that will justify their spending. But the experience of Merck suggests the costs can be spread across the business, with manufacturing teams finding the data analytics tools as useful as their peers in R&D do.

Billionaire-backed startup puts Big Data, AI at the heart of drug discovery

The features of Berg Pharma's discovery platform read like a bingo card of hyped approaches, with Big Data sitting alongside genomics and artificial intelligence. Berg has tried to push expectations higher still by claiming it can halve drug development time and costs, but to date the claims--like some of the technologies on which they are based--remain unproven.

Merck puts big data to work to solve vaccine manufacturing concern

Big data analytics have become a common consideration in the R&D part of the pharmaceutical industry, allowing researchers to search and share remarkable amounts of data points. But Merck & Co. has turned to the process to solve a manufacturing problem and potentially save hundreds of millions of dollars in the process.

NIH looking to research community for data and metadata standards

Over the past 18 months the National Institutes of Health has taken multiple steps to get a grip on spiraling Big Data challenges, but the initiatives are still taking shape. And the agency is seeking the input of the genomics, bioinformatics and broader medical communities to help finalize its plans.

GSK teams up to apply Big Data to target validation

The combination of genomics and bioinformatics expertise now needed for target validation has led drugmakers to look outside their walls for skills, with Pfizer teaming with the Broad Institute on such a project. Now GlaxoSmithKline has set up its own initiative and called for its Big Pharma peers to get involved.

Busy week at Intel bolsters its presence in life sciences

Falling sales of personal computers have chipped away at one of the cornerstones of Intel's business over the past few years. The chipmaker has responded by diversifying and this week made three such moves, each of which has implications for the life sciences sector.

Big Data's double-edged sword: Better drug marketing, bigger SG&A cost cuts

Big Data could be a big deal for Big Pharma's commercial operations. It could help top drugmakers slash another $35 billion-plus in costs over the next several years, to keep margins up. But it's small drugmakers that could benefit most strategically, a new report finds.

Report: Big Data, social media and mobile double their share of biopharma marketing mix

Over the past decade a plethora of digital formats have begun competing with print, television, radio and conferences for biopharma marketeers' budgets. And while initial uptake was slow, a survey has now found Big Data, social media and mobile have doubled their share of the marketing mix since 2012.

U.K. begins trying to rebuild trust in patient database after months of 'confusion, suspicion and anxiety'

The United Kingdom's long history of public healthcare gives it an enviable trove of patient data. Yet this resource, which is perhaps the one true competitive edge possessed by U.K. biopharma, is at risk of being squandered as the project continues to buried by mismanagement and a blizzard of negative publicity.